ESR1 and breast carcinoma: Additionally, due to constraints in the composition of the GWAS database, this study only performed bidirectional two-sample Mendelian randomization analyses on ER+ and ER-breast cancer subtypes, precluding further analysis based on different HER2, PR, or even AR expression statuses.